PTAB institutes IPRs on Sanofi patents

The US Patent Trial and Appeal Board (PTAB) has instituted inter partes reviews (IPRs) of two patents owned by Sanofi covering Lantus (insulin glargine injection).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi wins SCOTUS stay of Lantus patent dispute

13 February 2020 Pharmaceutical company Sanofi has been granted a stay by the US Supreme Court in its ongoing patent litigation battle with Netherlands-based Mylan.

Americas

Sanofi takes on Mylan over diabetes injection

25 October 2017 Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.

Americas

Sanofi sues Merck over Lantus patents

21 September 2016 Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus and Lantus SoloSTAR.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

PTAB institutes IPRs on Sanofi patents

More on this story

Editor's picks

Editor's picks

More features